Catalog No.
Product Name
Application
Product Information
Citations
-
COX inhibitor
2-Chloro-N-(2,6-dimethylphenyl)acetamide is a cyclooxygenase (COX) inhibitor that modulates inflammatory responses by inhibiting the conversion of arachidonic acid to prostaglandins. Its biological activity makes it a valuable tool in research focused on inflammation and pain pathways. This compound is utilized for studying COX-related mechanisms in various biological contexts, potentially aiding in the development of anti-inflammatory therapies. -
COX- 2 Inhibitor
Ocarocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 1.4 μM. By inhibiting COX-2, Ocarocoxib effectively reduces the synthesis of prostaglandins, thereby imparting significant anti-inflammatory effects. This compound is useful for research on inflammation and associated pathological conditions. -
COX-2/5-LOX Inhibitor
Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases. -
COX-1 Inhibitor
Teriflunomide impurity 3, also known as 4-Amino-N-(4-trifluoromethylphenyl)benzamide, acts as a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 of 30 µM. This compound exhibits significantly lower activity against COX-2, with an IC50 greater than 100 µM. Teriflunomide impurity 3 is valuable for research applications exploring inflammatory pathways and the role of COX-1 in various biological processes. -
COX
ASP6537 is a selective inhibitor of recombinant human cyclooxygenase-1 (rhCOX-1), exhibiting an IC50 value of 0.703 nM. Its potent inhibition of COX-1 makes it a valuable tool for studying the role of prostaglandins in cardiovascular disease research. Researchers can utilize ASP6537 to investigate the effects of COX-1 modulation on cardiovascular pathophysiology. -
iNOS/COX-2 Inhibitor
Rehmapicrogenin is a selective inhibitor of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). This compound, derived from the root of Rehmannia glutinosa, demonstrates significant anti-inflammatory properties, making it a valuable tool for research focused on inflammation pathways. Its ability to inhibit pro-inflammatory mediators such as IL-6 further underscores its relevance in studies aimed at understanding and treating inflammatory diseases. -
COX-1/COX-2 Inhibitor
(S)-(+)-Ibuprofen-d3 is a deuterated analog of (S)-(+)-Ibuprofen, targeting the COX-1 and COX-2 enzymes. With IC50 values of 2.1 μM and 1.6 μM, respectively, this compound exhibits significant analgesic, anti-inflammatory, and antipyretic properties. It serves as a valuable tool for studying the pharmacodynamics and mechanisms of nonsteroidal anti-inflammatory drugs (NSAIDs) in various biological research applications. -
COX Inhibitor
Isoxicam is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Its primary mechanism involves the inhibition of prostaglandin synthesis, making it effective in reducing inflammation and pain. Isoxicam is commonly utilized in research related to arthritis and other inflammatory conditions, providing valuable insights into the role of COX enzymes in various biological processes. -
COX-2 Inhibitor
Cimicoxib is a selective COX-2 inhibitor that effectively penetrates the blood-brain barrier. It displays significant anti-inflammatory, analgesic, and antipyretic properties by inhibiting the production of thromboxane B2 and prostaglandin E2, with an IC50 of 66 nM against human COX-2. Additionally, Cimicoxib targets CYP2D15, exhibiting an IC50 of 1.6 μM in canines and 0.056 μM in felines. This compound is utilized in research involving inflammatory diseases, osteoarthritis, and perioperative pain management in orthopedic and soft tissue surgeries. -
COX Inhibitor
Naproxen glucuronide, a metabolite of naproxen, functions as a non-selective cyclooxygenase (COX) inhibitor. This compound exhibits significant anti-inflammatory, analgesic, and antipyretic activity, making it useful in the study of pain relief and inflammation pathways. Research applications include examining its metabolic pathways, assessing its efficacy in various inflammatory conditions, and exploring its pharmacokinetic properties in biological systems. -
Dual COX/5-LOX Inhibitor
ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts. -
COX-2 Inhibitor
Apricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating a potent inhibitory effect on PGE2 production with an IC50 of 1.5 nM. This compound exhibits notable biological activities, including anticancer, analgesic, and anti-inflammatory properties. Apricoxib is a valuable tool for research applications focused on inflammation, pain management, and cancer therapeutics. -
COX-2/PGE2 Inducer
Rebamipide-d4 is a deuterium-labeled derivative of Rebamipide, primarily targeting cyclooxygenase-2 (COX-2). This compound induces COX-2 expression and elevates prostaglandin E2 (PGE2) levels, thereby enhancing gastric mucosal defense mechanisms in a COX-2-dependent manner. Rebamipide-d4 is utilized in various research applications focused on gastric protection and the modulation of inflammatory responses. -
Alkaloid
(S)-Laudanosine is an alkaloid with a primary action on the central nervous system and cardiovascular system. It inhibits low-affinity GABA receptors, exhibiting an IC50 value of 10 μM and has the potential to induce seizures, hypotension, and bradycardia. Additionally, (S)-Laudanosine demonstrates analgesic properties through competitive binding to the opioid Mu-1 receptor, with a binding affinity characterized by a Ki value of 2.7 μM. This compound is valuable for research into neurological and cardiovascular functions. -
Phosmet Metabolite
Phosmet oxon is a potent metabolite of phosmet, functioning primarily as a cholinesterase inhibitor. This compound exhibits significant neurotoxic activity, making it relevant in studies investigating insecticidal mechanisms and their effects on cholinergic signaling pathways. Phosmet oxon's utility extends to research on pesticide metabolism and its implications for environmental toxicology and safety assessments. -
Corydaline Metabolite
Isocorybulbine is a primary metabolite of Corydaline, produced in human liver microsomes and liver cells. It exhibits significant biological activities, including anti-acetylcholinesterase and anti-allergic effects. This compound is valuable for metabolic studies of Corydaline, contributing to research in pharmacology and potential therapeutic applications. -
AChE Inhibitor
Donepezil N-oxide is an acetylcholinesterase (AChE) inhibitor derived from Donepezil. It exhibits significant biological activity by inhibiting AChE in human erythrocytes, which is crucial for regulating acetylcholine levels in neurological pathways. This reagent is utilized in research focused on Alzheimer's disease and other cognitive disorders where modulation of cholinergic transmission is a key area of investigation. -
Disulfoton Oxidation Metabolite
Demeton-S sulfone is the oxidative metabolite of the organophosphorus insecticide Disulfoton, primarily targeting acetylcholinesterase. This compound exhibits significant acetylcholinesterase inhibition, which is essential for studying neurotoxic effects related to organophosphate exposure. It serves as a crucial reagent for evaluating the biochemical pathways of organophosphate metabolism and understanding their environmental and health impacts. -
Pesticide Metabolite
Malaoxon is a pesticide metabolite that serves as an inhibitor of acetylcholinesterase, impacting neurotransmitter regulation. This compound has been shown to induce cellular death in cultured human pulmonary cells, making it relevant for studies on pulmonary toxicity and its underlying mechanisms. Its application extends to research focused on the toxicological effects of pesticide exposure in human respiratory systems. -
Drug Metabolite Control
4-Hydroxypentanoate sodium is an active metabolite of gamma-Valerolactone, functioning primarily as a sedative. Its primary mechanism involves modulation of GABA receptors, leading to enhanced inhibitory neurotransmission. This compound is utilized in pharmacological research to study drug metabolism and to evaluate sedative effects in various experimental models. -
Drug Metabolite Control
7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one is a primary metabolite of Flubromazepam, acting on the central nervous system through modulation of GABA receptors. This compound exhibits potential anxiolytic and sedative properties, making it relevant for studies on drug metabolism and pharmacokinetics. Its application is beneficial in research focused on benzodiazepine derivatives and their metabolic pathways. -
Etoricoxib Metabolite
Etoricoxib N1'-oxide is a metabolite of Etoricoxib that serves as an important biochemical marker in pharmacological studies. This compound is notable for its lack of inhibition on both COX-1 and COX-2 enzymes, making it a valuable tool for researchers investigating the metabolic pathways and safety profiles of COX inhibitors. Its characterization can aid in understanding the pharmacodynamics and pharmacokinetics of Etoricoxib in clinical settings. -
Alkaloid
Circumdatin C is an alkaloid that demonstrates inhibitory effects on lipopolysaccharide (LPS)-stimulated nitric oxide production. Additionally, it inhibits acetylcholinesterase (AChE) activity with an IC50 value of 13.9 μM. This compound is valuable for research into neurodegenerative diseases, particularly Alzheimer's disease, by exploring mechanisms related to neurotransmitter regulation and neuroinflammation. -
Antioxidant Agent
4-Hydroxyisophthalic acid functions primarily as an antioxidant agent, activating crucial antioxidant enzymes such as catalase (CAT) and superoxide dismutase (SOD). Its ability to scavenge free radicals contributes to its protective effects on neuronal function, as it enhances the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). In research applications, 4-Hydroxyisophthalic acid has demonstrated potential in improving cognitive defects and alleviating circadian rhythm disorders in model organisms, such as fruit flies. -
Stable Isotope
Imidazole-15N2 is a stable isotope-labeled derivative of imidazole, a heterocyclic aromatic compound. It serves as a valuable tool in metabolic studies and tracing experiments due to its nitrogen-15 labeling. Imidazole and its derivatives exhibit a wide range of biological activities, including inhibition of acetylcholinesterase and xanthine oxidase, as well as properties such as antifungal, antituberculosis, anti-inflammatory, and antioxidant effects. Additionally, imidazole derivatives have shown promise in the inhibition of SARS-CoV-2 3CLPro enzyme, highlighting their potential applications in research related to Alzheimer's disease, gout, COVID-19, and thromboembolic disorders. -
COX Inhibitor
SC57666 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 26 nM. This compound exhibits anti-inflammatory activity by specifically blocking COX-2, thereby reducing prostaglandin synthesis. SC57666 is valuable for research applications focused on understanding inflammation and pain mechanisms, as well as for screening in drug discovery efforts targeting COX-2 related conditions. -
COX Inhibitor
FR-188582 is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 17 nM. This compound exhibits potent anti-inflammatory activity, making it a valuable tool for studies related to pain and inflammation pathways. Its specificity for COX-2 allows for the exploration of therapeutic applications in conditions such as arthritis and other inflammatory diseases. -
COX Inhibitor
Nitroflurbiprofen is a cyclooxygenase (COX) inhibitor known for its nitric oxide (NO)-donating properties. It effectively modulates increased intrahepatic vascular tone, making it a valuable tool in studying portal hypertension and liver diseases. This compound is utilized in research contexts focused on the therapeutic mechanisms of COX inhibition and its impact on hepatic vascular dynamics. -
COX Inhibitor
RWJ 63556 is an orally active inhibitor of cyclooxygenase-2 (COX-2) and a 5-lipoxygenase inhibitor, exhibiting significant anti-inflammatory properties. This compound is utilized in research to explore its potential therapeutic effects in conditions characterized by inflammation, such as arthritis and other inflammatory diseases. Its selective inhibition may provide insights into the role of COX-2 and lipoxygenase pathways in various biological processes. -
COX Inhibitor
COX-2-IN-6 is a selective cyclooxygenase-2 (COX-2) inhibitor, specifically designed for oral administration and exhibiting gut-restricted properties. With an IC50 value of 0.84 μM and a Ki of 69 nM, COX-2-IN-6 effectively targets COX-2, inhibiting COX-2-driven PGE2 synthesis with an IC50 of 0.60 μM. This compound is utilized in research focused on colorectal cancer chemoprevention, offering valuable insights into inflammatory processes and therapeutic strategies. -
COX-2 Inhibitor
COX-2-IN-28 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.054 µM for COX-2, while demonstrating significantly lower inhibitory activity against 15-lipoxygenase (2.14 µM) and cyclooxygenase-1 (13.21 µM). This selective inhibition positions COX-2-IN-28 as a valuable tool for investigating the role of COX-2 in inflammation and pain pathways. It is suitable for research applications focused on inflammatory diseases and therapeutic development targeting COX-2 pathways. -
COX Inhibitor
Tolmetin sodium is a potent inhibitor of cyclooxygenase (COX), demonstrating IC50 values of 0.35 μM for human COX-1 and 0.82 μM for COX-2. As a non-steroidal anti-inflammatory drug (NSAID), it is primarily used for its analgesic and anti-inflammatory properties. Tolmetin sodium is valuable in research applications focused on pain management, inflammation, and associated disorders. -
COX-2 Inhibitor
SD 8381 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2). It demonstrates an IC50 value of 0.0098 μM against human COX-2 and 0.69 μM against human COX-1, indicating a high degree of selectivity. This compound is valuable for research applications focused on inflammation and pain management, as well as studies examining the role of COX-2 in various disease states. -
COX2 Inhibitor
COX-2-IN-56 is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating minimal inhibition of cyclooxygenase-1 (COX-1). This compound is valuable for investigating COX-2-dependent disorders, particularly in the context of inflammatory processes. Its specificity makes it suitable for research applications focused on understanding the role of COX-2 in various pathological conditions. -
COX Inhibitor
Benzoylgomisin O is a selective inhibitor of cyclooxygenase enzymes COX-1 and COX-2, as well as 15-lipoxygenase (15-LOX). This compound, isolated from Schisandra rubriflora, exhibits significant anti-inflammatory activity, making it a valuable reagent for research into inflammatory diseases and related pathways. Its ability to modulate lipid mediators positions it as a potential tool in the study of pathophysiological conditions where COX and LOX pathways are implicated. -
COX-1 inhibitor
COX-1-IN-1 is a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 value of 0.23 μM, demonstrating a high degree of selectivity over COX-2 (IC50 > 50 μM), resulting in a selectivity index of 217. This compound effectively inhibits platelet aggregation, making it a useful tool in the study of inflammatory processes and cardiovascular research applications. COX-1-IN-1 can aid in understanding the role of COX-1 in various physiological and pathological conditions. -
COX-2 Inhibitor
Desmethyl etoricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 1 μM in whole blood, demonstrating significant potential in modulating inflammatory responses. It exhibits a lower affinity for COX-1, with an IC50 of 16 μM in U937 cells, highlighting its selectivity. This compound is valuable for research applications targeting inflammatory pathways and exploring therapeutic effects in various inflammatory conditions. -
COX1/2 Inhibitor
COX-1/2-IN-2 is a selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), demonstrating potent activity with IC50 values of 9.7 ± 0.09 µM for COX-1 and 4.6 ± 1.45 µM for COX-2. This compound is useful in research applications involving inflammation and pain modulation, as it effectively reduces the synthesis of pro-inflammatory prostaglandins. Its utility in pharmacological studies makes it a valuable reagent for exploring COX-related pathways. -
COX-2 Inhibitor
Cassiatannin A is a proanthocyanidin tetramer that acts as a selective COX-2 inhibitor. It has demonstrated significant inhibition rates of 38%, 52%, and 97% at concentrations of 10, 100, and 1000 μg/mL, respectively. This compound is valuable for research into inflammatory processes and the molecular pathways associated with COX-2-mediated responses. -
COX-2 Inhibitor
COX-2-IN-21 is a selective, orally active inhibitor of cyclooxygenase-2 (COX-2) with an IC50 of 0.039 μM. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory diseases and pain management. Its selectivity for COX-2 over COX-1 enhances its therapeutic potential while minimizing side effects associated with non-selective NSAIDs. -
iNOS/COX-2 Inhibitor
Longiferone B is a daucane sesquiterpene derived from the rhizomes of Boesenbergia longiflora, acting as an inhibitor of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). It exhibits significant anti-inflammatory properties, effectively reducing nitric oxide production with an IC50 value of 21.0 μM. Longiferone B also suppresses the mRNA expression of iNOS and COX-2, making it a valuable compound for research in inflammation-related studies. -
COX-2 Inhibitor
COX-2-IN-27 is a potent and selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 of 0.045 µM against COX-2, while demonstrating significantly higher IC50 values of 13.22 µM for COX-1 and 1.67 µM for 15-lipoxygenase (15-LOX). This compound exhibits notable anti-inflammatory activity, making it a valuable tool for research in inflammation-related pathways and the study of COX-2 mediated processes. Its selectivity enables detailed investigations into the role of COX-2 in disease and therapeutic applications. -
COX-1 Inhibitor
VU0487836 is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting an IC50 value of 0.36 μM against ovine-derived COX-1. This compound is being investigated as a prototype for developing radiological imaging agents aimed at COX-1 in ovarian cancer. VU0487836 is relevant for research focused on ovarian cancer and may provide insights into therapeutic strategies targeting COX-1 pathways. -
COX-2 Inhibitor
LM-4108 (N-(2-Phenylethyl)-indomethacin amide) is a selective and orally active inhibitor of COX-2, demonstrating an IC50 of 0.06 μM against purified human COX-2. This compound exhibits significant anti-inflammatory properties and has potential applications in cancer prevention. The metabolic stability of LM-4108 varies across species, with half-lives of 11 minutes in rat, 21 minutes in human, and 51 minutes in mouse liver microsomes. -
COX-2 Inhibitor
COX-2-IN-5 is a selective inhibitor of cyclooxygenase-2 (COX-2), exhibiting an IC50 value of 0.65 µM. This compound is primarily utilized in research focused on inflammation and related pathways. Its potent inhibitory activity makes it an invaluable tool for studying COX-2 mediated processes in various biological contexts. -
COX-2/5-LOX Inhibitor
COX-2/5-LOX-IN-2 is a potent dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX). This benzothiophen-2-yl pyrazole carboxylic acid derivative demonstrates significant analgesic and anti-inflammatory properties, exhibiting COX-2 inhibitory activity with an IC50 of 0.01 μM and 5-LOX inhibitory activity with an IC50 of 1.78 μM. COX-2/5-LOX-IN-2 is a valuable tool for research applications aimed at understanding and modulating inflammatory pathways. -
COX Inhibitor
Plantanone A is a selective cyclooxygenase (COX) inhibitor, demonstrating an IC50 of 33.37 μM for ovine COX-1 and 46.16 μM for ovine COX-2. This compound exhibits limited DPPH radical scavenging activity with an IC50 of 467.7 μM. Plantanone A serves as a valuable tool for investigating inflammation-related diseases and their underlying mechanisms. -
COX-2 Inhibitor
COX-2-IN-17 is a potent inhibitor of cyclooxygenase-2 (COX-2) with a remarkable ability to penetrate the blood-brain barrier (BBB), exhibiting an IC50 of 0.02 μM. This compound demonstrates significant anti-inflammatory and analgesic properties, effectively reducing hyperalgesia during both the neurogenic and inflammatory phases. COX-2-IN-17 is suitable for research applications aimed at understanding pain mechanisms and exploring potential therapeutic interventions for inflammatory conditions. -
COX-1/2 Inhibitor
N-Acetyl-2-carboxybenzenesulfonamide is a potent inhibitor of COX-1 and COX-2, exhibiting IC50 values of 0.06 μM and 0.25 μM, respectively. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for the study of inflammatory pathways and the development of anti-inflammatory therapies. Its ability to selectively inhibit cyclooxygenase enzymes positions it as a useful agent in pharmacological research. -
COX-2 Inhibitor
COX-2-IN-51 is a selective COX-2 inhibitor exhibiting an IC50 of 70.7 nM. It effectively reduces LPS-induced release of nitric oxide (NO) and prostaglandin E2 (PGE2), as well as the expression of COX-2 and inducible nitric oxide synthase (iNOS), and inhibits the NF-κB signaling pathway. This compound demonstrates anti-inflammatory and analgesic properties in various murine models by targeting the NF-κB cascade, while presenting a lower risk of gastrointestinal side effects compared to traditional nonsteroidal anti-inflammatory drugs.
